Overview
Coho VC supports deep science and technology ventures at the edge of what is possible by funding and incubating them at the earliest stages. It combines life science and computer science to engineer and manipulate biology and develop fundamentally new tools, with the aim of creating frontier technologies that can achieve significant revenue and global traction, improve lives, and protect the planet. The company derisks and scales ventures by providing not just capital but hands-on support, mentorship, and resources to help founders move from concept to scalable, impactful businesses. Compared with others, Coho VC emphasizes early-stage funding for cross-disciplinary, high-risk frontier projects and pairs financial investment with active incubation to accelerate progress and reduce risk. Its goal is to push frontier science into practical, globally impactful products and companies that deliver measurable value beyond the financials.
Work here?Claim your company
Simplify's take
What believers are saying
- Assort Health closed a $120M Series C on June 24, 2026.
- Odyssey raised $310M on June 20, 2026, validating Coho's physical-world thesis.
- Higgsfield reached $200M annual run rate by January 15, 2026.
What critics are saying
- Coho discloses one portfolio company publicly on startuphub.ai, signaling thin reporting transparency.
- Its X feed stopped at June 25, 2026, reducing recruiting and brand momentum.
- If Assort Health, Odyssey, or Higgsfield stall, Coho loses its flagship proof points. That failure blocks fundraising and ends Coho Deeptech's edge-brand within 12 months.
What makes Coho VC unique
- Coho Deeptech backs seed-stage frontier founders at biology-computing intersections from San Francisco since 2022.
- Its portfolio spans Assort Health, Odyssey, Bland, Cartesia, and Starling Medical.
- The firm emphasizes incubating companies toward significant revenue and global traction.
Help us improve and share your feedback! Did you find this helpful?